Document is current
Any future updates will be listed below
-
Authors
Solé, Patricia
Yamanouchi, Jun
Garnica, Josep https://orcid.org/0000-0001-9493-1321
Uddin, Muhammad Myn
Clarke, Robert
Moro, Joel
Garabatos, Nahir
Thiessen, Shari
Ortega, Mireia
Singha, Santiswarup
Mondal, Debajyoti
Fandos, César
Saez-Rodriguez, Julio
Yang, Yang
Serra, Pau
Santamaria, Pere https://orcid.org/0000-0003-3469-1586
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
- License Information
-
More Information
Article History
Received: 7 September 2022
Accepted: 12 February 2023
First Online: 27 March 2023
Competing interests
: P. Santamaria is founder, scientific officer and stockholder of Parvus Therapeutics. He is listed as an inventor on patents on pMHC-based nanomedicines and receives funding from the company. JSR received funding from GSK and Sanofi and consultant fees from Travere Therapeutics.
